|
Κυριακή 13 Δεκεμβρίου 2020
A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Related Articles Snus und die Beeinträchtigungen der Mundgesundheit: Ein Update. Swiss Dent J. 2016;126(9):799-811 Authors: Sieber A...
-
Publication date: Available online 22 September 2016 Source: Acta Biomaterialia Author(s): Mian Wang, Pelagie Favi, Xiaoqian Cheng, Negar ...
-
Abstract Background Tumor cell mediated immune-suppression remains a question of interest in tumor biology. In this study, we focused on...
-
Publication date: Available online 29 September 2016 Source: Brazilian Journal of Otorhinolaryngology Author(s): Carlos Miguel Chiesa Esto...
-
Oral manifestations of dengue fever Sethuraman Govindaraj, Ramesh Jayaraman, M Jonathan Daniel, Saravanan Subbiah, Srinivasan Subramanian Va...
-
http://www.jgmh.org/currentissue.asp?sabs=y Mobile phone use in the elderly: Boon or bane? Alka A Subramanyam, Shipra Singh, Nitin B Raut Jo...
-
Publication date: 15 January 2017 Source: Applied Surface Science, Volume 392 Author(s): Pei Wang, Lin Tang, Xue Wei, Guangming Zeng, Yaoy...
-
Publication date: Available online 28 September 2016 Source: American Journal of Otolaryngology Author(s): K. Adachi, T. Umezaki Purpose...
-
In the present study, spray-dried nanoparticles-in-microparticles system (NiMS) of Acetazolamide (ACZ) was formulated for preparing orally d...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου